T2 stretches out globally with sepsis assays

By LabPulse.com staff writers

July 30, 2019 -- T2 Biosystems is introducing its T2Bacteria and T2Candida whole-blood panel diagnostics in five new countries -- Estonia, Greece, Ireland, Saudi Arabia, and South Africa -- through new distribution deals.

Both panel tests are cleared by the U.S. Food and Drug Administration, are used with the company's T2Dx miniaturized magnetic resonance instrument, and provide results from whole blood within three to five hours, according to the company.

The T2Bacteria panel tests for types of bacteria that cause sepsis, while the T2Candida panel tests for fungal pathogens.

Microfluidic device could enable faster sepsis diagnosis
A microfluidic device being developed at the Massachusetts Institute of Technology (MIT) could enable sepsis to be diagnosed more quickly and with a smaller...
iCubate's iC-GN Gram-negative assay clears FDA
iCubate has announced that its iC-GN assay has been cleared by the U.S. Food and Drug Administration (FDA) for use with its iCubate multiplex polymerase...
FDA clears 2 Hologic tests for yeast infections
The U.S. Food and Drug Administration (FDA) has cleared two diagnostic tests from Hologic for diagnosing vaginitis, or yeast infections, the company announced...
T2Bacteria panel proves itself, but will hospitals buy in?
The T2Bacteria panel was accurate and fast for detecting five common kinds of bacteria in the blood in a multicenter study published May 13 in the Annals...

Copyright © 2019 LabPulse.com

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current